Chronic pain therapy and hypothalamic-pituitary-adrenal axis impairment

Psychoneuroendocrinology

Volumn 36, Issue 7, 2011, Pages 1032-1039

  Aloisi, Anna Maria ^a,b   Buonocore, Michelangelo ^a   Merlo, Laura ^a   Galandra, Caterina ^a   Sotgiu, Alberto ^a   Bacchella, Luisa ^a   Ungaretti, Marina ^a   Demartini, Laura ^a   Bonezzi, Cesare ^a  

^a IRCCS   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Hypothalamic pituitary adrenal axis; NSAIDs; Opiates; Pain; Sex differences

Indexed keywords

ACETYLSALICYLIC ACID; CARBAMAZEPINE; CODEINE; CORTICOTROPIN; FENTANYL; GABAPENTIN; HYDROCORTISONE; IBUPROFEN; MORPHINE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PRASTERONE; PRASTERONE SULFATE; PREGABALIN; TRAMADOL;

ADULT; AGED; ANXIETY; ARTICLE; BRAIN FUNCTION; CHRONIC PAIN; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE DISEASE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; MALE; PERCEPTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; SEX DIFFERENCE; TREATMENT INDICATION;

ADRENOCORTICOTROPIC HORMONE; ADULT; AGE FACTORS; AGED; ANALGESICS; CASE-CONTROL STUDIES; CHRONIC PAIN; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; SEX FACTORS;

EID: 79960570862     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2010.12.017     Document Type: Article

References (41)

1. Abs R., Verhelst J., Van Buyten J.P., Opsomer F., Adriaensen H., Verlooy J., Van Havenbergh T., Smet M., Van Acker K. Endocrine consequences of long-term intrathecal administration of opioids. J. Clin. Endocrinol. Metab. 2000, 85:2215-2222.
2. Aloisi A.M., Aurilio C., Bachiocco V., Biasi G., Fiorenzani P., Pace M.C., Paci V., Pari G., Passavanti G., Ravaioli L., Sindaco G., Vellucci R., Ceccarelli I. Endocrine consequences of opioid therapy. Psychoneuroendocrinology 2009, 34:S162-S168.
3. Aloisi A.M., Ceccarelli I., Fiorenzani P., Maddalena M., Rossi A., Tomei V., Sorda G., Danielli B., Rovini M., Cappelli A., Anzini M., Giordano A. Aromatase and 5-alpha reductase gene expression: modulation by pain and morphine treatment in male rats. Mol. Pain 2010, 26(October 6):69. (PMID: 20977699 [PubMed - in process]).
4. Aloisi A.M., Pari G., Ceccarelli I., Vecchi I., Ietta F., Lodi L., Paulesu L. Gender-related effects of chronic non-malignant pain and opioid therapy on plasma levels of macrophage migration inhibitory factor (MIF). Pain 2005, 115:142-151.
5. Arlt W. Dehydroepiandrosterone and ageing. Best Pract. Res. Clin. Endocrinol. Metab. 2004, 18:363-380.
6. Bastianetto S., Ramassamy C., Poirier J., Quirion R. Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Brain Res. Mol. Brain Res. 1999, 66:35-41.
7. Beck A.T., Steer R.A., Ball R., Ranieri W. Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients. J. Pers. Assess. 1996, 67:588-597.
8. Beck A.T., Epstein N., Brown G., Steer R.A. An inventory for measuring clinical anxiety: psychometric properties. J. Consult. Clin. Psychol. 1988, 56:893-897.
9. Böhmelt A.H., Nater U.M., Franke S., Hellhammer D.H., Ehlert U. Basal and stimulated hypothalamic-pituitary-adrenal axis activity in patients with functional gastrointestinal disorders and healthy controls. Psychosom. Med. 2005, 67:288-294.
10. Bologa L., Sharma J., Roberts E. Dehydroepiandrosterone and its sulfated derivative reduce neuronal death and enhance astrocytic differentiation in brain cell cultures. J. Neurosci. Res. 1987, 17:225-234.
11. Camí J., Gilabert M., San L., de la Torre R. Hypercortisolism after opioid discontinuation in rapid detoxification of heroin addicts. Br. J. Addict. 1992, 87:1145-1151.
12. Cardounel A., Regelson W., Kalimi M. Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proc. Soc. Exp. Biol. Med. 1999, 222:145-149.
13. Chang L., Sundaresh S., Elliott J., Anton P.A., Baldi P., Licudine A., Mayer M., Vuong T., Hirano M., Naliboff B.D., Ameen V.Z., Mayer E.A. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol. Motil. 2009, 21:149-159.
14. Daniell H.W. DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. J. Pain 2006, 7:901-907.
15. Daniell H.W. Opioid-induced androgen deficiency discussion in opioid contracts. Am. J. Med. 2007, 120:21.
16. Daniell H.W. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J. Pain 2008, 9:28-36.
17. Darnaudéry M., Pallarès M., Piazza P.V., Le Moal M., Mayo W. The neurosteroid pregnenolone sulfate infused into the medial septum nucleus increases hippocampal acetylcholine and spatial memory in rats. Brain Res. 2002, 951:237-242.
18. De Benedittis G., Massei R., Nobili R., Pieri A. The Italian pain questionnaire. Pain 1988, 33:53-62.
19. Finch P.M., Roberts L.J., Price L., Hadlow N.C., Pullan P.T. Hypogonadism in patients treated with intrathecal morphine. Cl. J. Pain 2000, 16:251-254.
20. Gaab J., Baumann S., Budnoik A., Gmünder H., Hottinger N., Ehlert U. Reduced reactivity and enhanced negative feedback sensitivity of the hypothalamus-pituitary-adrenal axis in chronic whiplash-associated disorder. Pain 2005, 119:219-224.
21. Galli U., Gaab J., Ettlin D.A., Ruggia F., Ehlert U., Palla S. Enhanced negative feedback sensitivity of the hypothalamus-pituitary-adrenal axis in chronic myogenous facial pain. Eur. J. Pain 2009, 13:600-605.
22. Garcia-Segura L.M., Veiga S., Sierra A., Melcangi R.C., Azcoitia I. Aromatase: a neuroprotective enzyme. Prog. Neurobiol. 2003, 71:31-41.
23. Griep E.N., Boersma J.W., Lentjes E.G., Prins A.P., van der Korst J.K., de Kloet E.R. Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J. Rheumatol. 1998, 25:1374-1381.
24. Gur A., Cevik R., Nas K., Colpan L., Sarac S. Cortisol and hypothalamic-pituitary-gonadal axis hormones in follicular-phase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormones. Arthritis Res. Ther. 2004, 6:232-238.
25. Heim C., Ehlert U., Hanker J.P., Hellhammer D.H. Abuse-related posttraumatic stress disorder and alterations of the hypothalamic-pituitary-adrenal axis in women with chronic pelvic pain. Psychosom. Med. 1998, 60:309-318.
26. Kaasik A., Kalda A., Jaako K., Zharkovsky A. Dehydroepiandrosterone sulphate prevents oxygen-glucose deprivation-induced injury in cerebellar granule cell culture. Neuroscience 2001, 102:427-432.
27. Kibaly C., Meyer L., Patte-Mensah C., Mensah-Nyagan A.G. Biochemical and functional evidence for the control of pain mechanisms by dehydroepiandrosterone endogenously synthesized in the spinal cord. FASEB J. 2008, 22:93-104.
28. Kimonides V.G., Spillantini M.G., Sofroniew M.V., Fawcett J.W., Herbert J. Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures. Neuroscience 1999, 89:429-436.
29. Labrie F., Luu-The V., Bélanger A., Lin S.X., Simard J., Pelletier G., Latrie C. Is dehydroepiandrosterone a hormone?. J. Endocrinol. 2005, 187:169-196.
30. Manchikanti L., Fellows B., Vijay S. Understanding psychological aspects of chronic pain in interventional pain management. Pain Physician 2002, 5:57-82.
31. McBeth J., Chiu Y.H., Silman A.J., Ray D., Morriss R., Dickens C., Gupta A., Macfarlane G.J. Hypothalamic-pituitary-adrenal stress axis function and the relationship with chronic widespread pain and its antecedents. Arthritis Res. Ther. 2005, 7:992-1000.
32. Parker A.J., Wessely S., Cleare A.J. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol. Med. 2001, 31:1331-1345.
33. Riva R., Mork P.J., Westgaard R.H., Lundberg U. Fibromyalgia syndrome is associated with hypocortisolism. Int. J. Behav. Med. 2010, 17:223-233.
34. Tanriverdi F., Karaca Z., Unluhizarci K., Kelestimur F. The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. Stress 2007, 10:13-25.
35. Tomas-Camardiel M., Sanchez-Hidalgo M.C., Sanchez del Pino M.J., Navarro A., Machado A., Cano J. Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17beta-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum. Neuroscience 2002, 109:569-584.
36. Turner-Cobb J.M., Osborn M., da Silva L., Keogh E., Jessop D.S. Sex differences in hypothalamic-pituitary-adrenal axis function in patients with chronic pain syndrome. Stress 2010, 13:292-300.
37. Valença M.M., Medeiros F.L., Martins H.A., Massaud R.M., Peres M.F. Neuroendocrine dysfunction in fibromyalgia and migraine. Curr. Pain Headache Rep. 2009, 13:358-364.
38. Vallée M., Mayo W., Darnaudéry M., Corpéchot C., Young J., Koehl M., Le Moal M., Baulieu E.E., Robel P., Simon H. Neurosteroids: deficient cognitive performance in aged rats depends on low pregnenolone sulfate levels in the hippocampus. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:14865-14870.
39. Vallée M., Mayo W., Le Moal M. Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain Res. Rev. 2001, 37:301-312.
40. Ware J., Kosinski M., Keller S.D. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med. Care 1996, 34:220-233.
41. Zhou Q., Fillingim R.B., Riley J.L., Malarkey W.B., Verne G.N. Central and peripheral hypersensitivity in the irritable bowel syndrome. Pain 2010, 148:454-461.